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bAckground
Psoriatic arthritis (PsA) is a pleomorphic chronic in-
flammatory arthritis with a broad clinical spectrum, in-
cluding peripheral arthritis, spondylitis, enthesitis and
dactylitis, in association with skin and/or nail psoriasis.
Dactylitis and enthesitis are core PsA manifestations oc-
curring clinically in 30 to 50% of PsA patients, that can
severely impact health-related quality of life causing
pain and functional impairment1. Active dactylitis is
additionally an unfavorable prognostic factor associa -
ted with erosive disease and its relevance is further
suppor ted by its inclusion in the ClASsification for Pso-
riatic ARthritis (CASPAR) criteria2. 
The therapeutic strategies for dactylitis are, never-
theless, largely empirical and the interpretation of avai -
la ble data limited by the heterogeneity of the outcome
measures applied. The Group for Research and Assess-
ment of Psoriasis and Psoriatic Arthritis (GRAPPA) re-
view on dactylitis treatment highlights the paucity of
evidence in this field and the need for studies having
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AbstrAct
The GO-DACT is an investigator-initiated, multicen-
tric randomized placebo-controlled double-blinded 
trial, that assesses dactylitis as primary endpoint. Pso-
riatic arthritis patients naïve to methotrexate and bio-
logic disease modifying anti-rheumatic drugs, with at
least one active dactylitis, were assigned to golimumab
in combination with methotrexate or placebo in com-
bination with methotrexate, for 24 weeks. Both clini-
cal (dactylitis severity score and the Leeds dactylitis in-
dex) and imaging (high resolution magnetic resonance
imaging), among others, were assessed as outcomes.
The main objective of GO-DACT is to provide evidence
to improve the treatment algorithm and care of psoria -
tic arthritis patients with active dactylitis. In this
manuscript we describe the GO-DACT protocol and
general concepts of the methodology of this trial.
Keywords: Clinical trial; Dactylitis; Treatment algo-
rithm; Psoriatic arthritis
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dactylitis as the primary endpoint3,4. 
Most physicians will use non-steroidal anti-inflam-
matory drugs (NSAIDs) and corticosteroid injections
as first-line therapy, although they have not been for-
mally studied3,5. Considering conventional synthetic
disease modifying anti-rheumatic drugs (csDMARDs),
methotrexate (MTX) is recommended as first-choice
csDMARD for patients with active peripheral disease
that do not respond to NSAIDs and local corticos-
teroids, as the standard of practice, in several coun-
tries5-8. MTX lacks, however, evidence of efficacy from
randomized controlled trials in the treatment of both
dactylitis and enthesitis9. The most recently updated
European League Against Rheumatism (EULAR) re -
commendations consider the use of biologic DMARDs
(bDMARDs), preferentially tumor necrosis factor inhi -
bi tors (TNFi), in patients with dactylitis (and enthesi-
tis), even if no csDMARDs have been tried, but the fi-
nal decision to introduce a bDMARD is based on the
ge neral clinical judgment of the treating physician7.
Among TNFi, golimumab, a human TNFi monoclo -
nal antibody, has documented efficacy in improving
dactylitis and enthesitis, and adding MTX to golimu -
mab was associated with a further improvement of
10% in dactylitis, enthesitis and nail psoriasis scores in
randomized controlled trials10. However, as with other
available TNFi, the effects on dactylitis and enthesitis
have been reported only as secondary outcomes and
no previous randomized controlled trial has been per-
formed assessing dactylitis as primary endpoint. 
The treatment algorithm for dactylitis and enthesi-
tis is, therefore, still debatable, as evidenced by the low
levels of agreement in national and European guide-
lines, highlighting the need to generate data from ran-
domized controlled trials, aiming at the improvement
of clinical care6,7.
Taking these data altogether we hypothesized that
a better understanding of the therapeutic effect of goli-
mumab in association with MTX, in comparison with
MTX monotherapy, will contribute to improve the
management of dactylitis and enthesitis in psoriatic
arthritis patients.
study Aims
The aim of GO-DACT is to assess efficacy and safety of
golimumab in combination with MTX in comparison
with MTX monotherapy in the treatment of active
dactylitis, in MTX- and bDMARD-naïve PsA patients. 
PrimAry objective And endPoint
The primary objective of GO-DACT is to demonstrate
differences of efficacy of golimumab in combination
with MTX in comparison with MTX monotherapy, in
improving dactylitis at 24 weeks versus baseline, in
MTX- and bDMARD-naïve PsA patients.
The primary endpoint was defined as changes from
baseline in the Dactylitis Severity Score (DSS) at 24
weeks.
secondAry objectives And endPoints
The secondary objectives of GO-DACT are to assess
the efficacy of golimumab in combination with MTX
versus MTX monotherapy at 24 weeks, in MTX- and
bDMARD-naïve PsA patients on:
• Dactylitis using secondary endpoints such as:
changes from baseline in the DSS at 12 weeks, in
the Leeds Dactylitis Index (LDI) at 12 and 24 weeks;
the proportion of patients achieving DSS20, DSS50
and DSS70 at 12 and 24 weeks; the proportion of
patients achieving LDI20, LDI50 and LDI70 at 12
and 24 weeks; the proportion of patient achieving
dactylitis remission at 12 and 24 weeks, and the
proportion of patients with tender and non-tender
dactylitis at 12 and 24 weeks.
• Enthesitis based in changes from baseline in the
Leeds Enthesitis Index (LEI) and the Spondyloar -
thritis Research Consortium of Canada (SPARCC)
enthesitis score at 12 and 24 weeks; and the pro-
portion of patients achieving enthesitis remission at
12 and 24 weeks.
• Peripheral joint involvement using as endpoint the
changes from baseline in the 68 tender and the 66
swollen joint counts at 12 and 24 weeks.
• Patient’s and physician’s reported outcomes such as:
changes from baseline of patient and physician
disea se activity assessment using visual analogue
scales (VAS) at 12 and 24 weeks.
• Axial disease using changes from baseline of the
Bath Ankylosing Spondylitis Disease Activity Index
(BASDAI) and the Ankylosing Spondylitis Disease
Activity Score (ASDAS) at 12 and 24 weeks, in pa-
tients with axial involvement.
• Skin and nail psoriasis as assessed by the proportion
of patients achieving the Psoriasis Area and Severi-
ty Index (PASI) 50, 75 and 90 responses at 12 and
24 weeks, and the changes from baseline in the tar-
get Nail Psoriasis Severity Index (target NAPSI)
score, at week 12 and 24.
• Function defined by the changes from baseline in
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the functional indexes: Health Assessment Ques-
tionnaire Disability Index (HAQ-DI) and Bath Anky-
losing Spondylitis Functional Index (BASFI) at 12
and 24 weeks, as endpoints.
• Quality of life using changes from baseline in the
quality of life indexes: Medical Outcomes Study
Short Form 36 (SF-36) and Dermatology Life Quali -
ty Index (DLQI) at 12 and 24 weeks, as endpoint.
• Composite indexes of disease activity and response,
using the following endpoints: changes from base-
line in the Psoriatic Arthritis Disease Activity Score
(PASDAS), the Composite Psoriatic Disease Activity
Index (CPDAI), the Disease Activity Index for Pso-
riatic Arthritis (DAPSA), the Disease Activity Score
28 (DAS28), the Simplified Disease Activity Index
(SDAI), the Clinical Disease Activity Index (CDAI)
at week 12 and 24; and the proportion of patients
achieving the American College of Rheumatology
(ACR) 20, 50 and 70 response, the Psoriatic Arthri-
tis Response Criteria (PsARC) response, the Psoria -
tic Arthritis Joint Activity Index (PsAJAI) response,
the Assessment of Spondyloarthritis International
Society (ASAS) 20 and 40 response and the ASDAS
clinical important, major improvement and inactive
disease criteria, and the minimal disease activity
(MDA) at 12 and 24 weeks.
• Feet and hands inflammation assessed by magnetic
resonance imaging (MRI) defined by changes from
baseline in psoriatic arthritis MRI scoring system for
the hands (PSAMRIS-H) and for feet (PSAMRIS-F)
at week 24, and changes from baseline of dactylitis
MRI score at week 24.
The safety and tolerability of golimumab in combi-
nation with MTX versus MTX monotherapy were also
evaluated and the number of participants who expe -
rience an adverse event and that develop anti-golimu -
mab antibodies was determined.
metHodoLogy 
study design 
GO-DACT is an interventional investigator-initiated
randomized, double-blind, placebo-controlled, multi-
centric, 24 weeks, phase 3b, parallel design trial of goli-
mumab in combination with MTX versus MTX
monotherapy, in MTX- and bDMARD-naïve psoriatic
arthritis patients with active dactylitis. 
After a screening phase of approximately 28 days,
each subject received the assigned treatment for 24
weeks. At the end of treatment, each subject was
follow ed for safety monitoring and sustained efficacy 
assessment for 60 days after the last dosing visit (Fi -
gure 1).
Figure 1. Clinical trial diagram
methotrexate (MTX); visit (V)
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PAtient PoPuLAtion
Female and male patients, older than 18 years, with
the diagnosis of psoriatic arthritis according to the CAS-
PAR criteria, and at least one tender dactylitis and an-
other site of active inflammation (joints, enthesis, spine,
skin or nails), naïve to MTX and bDMARDs therapy,
refractory to at least two systemic NSAIDs, at optimal
dosage for 3 months, were eligible for inclusion. 
Key exclusion criteria were those considered for any
TNFi agent that could interfere with trial evaluations or
patients safety including: known or suspected allergy
to trial product or related products; current or chro nic
inflammatory autoimmune diseases other than PsA; 
active current infection or history of recurrent or chro -
nic infections, past (< 5 years) or current malignancy
with the exception of skin basal cell carcinoma; mode -
rate to severe heart failure (New York Heart Association
class III/IV); pre-existing central nervous system de-
myelinating disorders and any contra-indications to
perform MRI. Previous use of any bDMARDs and MTX
was prohibited. Previous local corticosteroids were al-
lowed, up to a maximum of two injection, adminis-
trated at least four weeks prior to screening. Other 
csDMARDs, except MTX, were also permitted if pre -
viously stopped according to their respective recom-
mend washout periods.
triAL Procedures
Recruitment and Informed consent
GO-DACT was approved by 13 Hospital Boards in Por-
tugal (Figure 2) including:
• Hospital de Santa Maria, Centro Hospitalar Lisboa
Norte, Lisboa
• Instituto Português de Reumatologia, Lisboa
• Hospital de Egas Moniz, Centro Hospitalar Lisboa
Ocidental, Lisboa
• Hospital de São João, Centro Hospitalar de São João,
Porto
• Hospital de Garcia de Orta, Almada
• Hospital Infante D. Pedro, Centro Hospitalar do
Baixo Vouga, Aveiro 
• Hospitais da Universidade de Coimbra, Centro Hos-
pitalar Universitário de Coimbra, Coimbra
• Unidade Local de Saúde do Alto Minho, Ponte de
Lima
• Centro Hospitalar de Vila Nova de Gaia, Vila Nova
de Gaia
• Hospital de São Teotónio, Viseu
Figure 2. Trial centres distribution in Portugal
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age, gender, or other demographic or diseases characte -
ristics was performed. Both patients and clinicians were
blinded for treatment assignments.
Visits schedule
The trial visits schema was defined aiming at mimi cking
the visit schedule used in clinical practice for patients
starting a bDMARD therapy. Subjects were asked to at-
tend a screening visit (visit 1), a baseline visit (vi sit 2),
two follow-up visits (visit 3 after 4 weeks and visit 4 af-
ter 12 weeks of baseline) and one end-of-study visit (vis-
it 5) at 24 weeks after baseline. It also inclu ded a safety
follow-up visit in person or by phone call (vi sit 6), for
a total of 6 visits during a period of 32 weeks (includ-
ing the screening period) (Figure 1 and Figure 4).
Pre-treatment assessment
Demographic information, previous relevant personal
and family medical history, previous and actual medi-
cation, physical examination including body mass in-
dex (BMI) (kg/m2) and organs and systems changes, as
well as smoking and alcohol intake, were registered.
• Hospital Particular do Algarve, Faro
• Hospital Distrital de Faro, Centro Hospitalar do Al-
garve, Faro
• Hospital de Santo Espírito de Angra do Heroísmo,
Ilha Terceira
Patients were recruited from rheumatology clinics
and a detailed patient information form with verbal ex-
planation of the trial was provided to all patients. Pa-
tients were given at least 24 hours to carefully read the
information, as well the opportunity to raise questions
before consenting their participation. Written informed
consent was obtained from all subjects before any 
trial activity. 
Randomization
PsA patients were centrally randomized to blinded,
eve ry four weeks subcutaneous injections of goli-
mumab 50 mg or to placebo, both in combination with
MTX, using a web-based randomization system of
Reuma.pt, the Rheumatic Diseases Portuguese Register
(Figure 3). Patients were randomly assigned in blocks
of 4 (2:2) to treatment arms. No stratification based on
Figure 3. Representation of the web-based randomization system of the Rheumatic Diseases Portuguese Register (Reuma.pt), available
at http://reuma.pt/random/randomization.html
Identification (ID)
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For disease characterization, the subtype of PsA accor -
ding to Moll and Wright classification criteria11, the date
of beginning of symptoms and of diagnosis, extra-ar-
ticular manifestations including uveitis, psoriasis, nail
dystrophy, dactylitis, enthesitis, Crohn’s disease, ulcera -
tive colitis, non-specific colitis and aortitis, the presen -
ce of rheumatoid factor, anti-cyclic citrullinated pepti -
des antibodies and the surface antigen human
leukocyte antigen (HLA) B27 were recorded in the
electro nic case report form (eCRF). Hand and feet
and/or axial radiographies were equally captured.
All patients were screened for hepatitis B and C, hu-
man immunodeficiency virus, active and latent tuber-
culosis, as according to local clinical practice, before
starting the trial medication. When indicated, treat-
ment for latent tuberculosis was implemented accor -
ding to local guidelines12,13. All women with child-bea -
ring potential were screened for pregnancy and all
patients performed an electrocardiogram (ECG).
Prior, Concomitant and Rescue Medications
Patients could not have been previously treated with
MTX or any bDMARDs. If under treatment with 
csDMARDs (other than MTX) or corticosteroids, pa-
tients had to be withdrawn from these therapies, accor -
ding to their respective recommend washout periods.
No other csDMARDs (with the exception of MTX) or
oral corticosteroids were allowed during the trial. Up
to a maximum of two local corticosteroids injections
were permitted, administrated at least four weeks 
prior to screening. Subjects could not have received
any investigational drugs within the 30 days prior to
baseline and could not receive them during the trial.
During the conduct of the trial, the physician was al-
lowed to use intra-articular injections of corticosteroids
as rescue medication, with exception of hands and feet
joints. The injection, if deemed necessary, was required
to occur at least 4 weeks prior to the next scheduled
exa mination. Joints injected with corticosteroids were
counted as tender and swollen at each visit taking place
within 4 months after the intra articular injection. 
Subjects were also allowed to take analgesics as rescue
medi cation. The dose and frequency of all rescue me -
dications needed to be registered in the eCRF and sub-
jects were advised not to take any analgesic medication
within 6 hours prior to the visits for dactylitis, joint
and enthesis evaluation.
Any concomitant medications (including over-the-
-counter medications, herbal medications, preventa-
tive vaccines, vitamins and food supplements) and pro-
cedures were recorded in the eCRF. A description of
the type of drug or procedure, the amount, duration,
reason for administration and outcome had to be docu -
mented. Any adverse event (AE) related to the admi -
nistration of a concomitant medication or procedure
had to be documented on the appropriate AE page of
the eCRF. 
If concomitant medication was changed because of
abnormal laboratory values of clinical significance, side
effects, concurrent illness, or performance of a surgical
procedure, the reason for the change had to be clearly
documented in the subject’s medical record.
Study intervention
Patients were randomized to one of the treatment arms:
golimumab in combination with MTX versus placebo
in combination with MTX.
Both golimumab 50 mg and placebo sterile solutions
were presented as a 0.5 ml pre-filled syringe, indistin-
guishable from each other: no difference in the appea -
rance of the two solutions was detectable. Golimumab
or placebo were administered subcutaneously, every
four weeks, for 24 consecutive weeks. Pre-filled sy-
ringes were labeled according to randomization num-
bers and sent to trial sites.
MTX was recommended to be started at a dose of
15mg/week, increased to 20mg/week at week 4 and
aiming at 25mg/week at week 8, according to patient
tolerability. 
MTX was taken orally, once a week, for 6 successive
months. Folic acid was given at least 24 hours after
MTX intake, at a dose between 5 and 25mg once a
week, according to the investigator s judgment. For pa-
tients that showed gastrointestinal intolerance to oral
MTX, switching to the subcutaneous formulation was
allowed.
Laboratory evaluations
Laboratory evaluations were performed as required in
clinical practice for monitoring golimumab and MTX
(Figure 4). These included:
• Hemoglobin, hematocrit, red blood cells and indices
(mean corpuscular volume, mean corpuscular
hemoglobin, mean corpuscular hemoglobin con-
centration), white blood cells and absolute differen-
tial, platelet counts, creatinine, aspartate amino-
transferase, alanine aminotransferase, C reactive
Protein, erythrocyte sedimentation rate (using 
Wes tergren method) and type II urine including
micros copic examination, at eve ry determination 
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Figure 4. Trial flow-chart
1 Visit name abbreviations: End of Treatment (EOT), End of Study (EOS) and Follow-up visit (FU).
2 Golimumab/methotrexate (MTX) and placebo/MTX injection administered up to seven days after study visit at which the protocol designated
study assessments are conducted.
3 Pregnancy tests conducted for female patients with child bearing potential. 
4 Tuberculosis screening performed according to local guidelines.
5 One electrocardiogram (ECG) obtained during screening. 
6 Hematology, chemistry, urinalysis.
7 Feet and ankle or hand and wrist magnetic resonance imaging (MRI) performed within up to 2 weeks before baseline visit and up to two weeks
after V5.
8 For patients that experience early termination, the end of study visit was anticipated.
Human leukocyte antigen B27 (HLAB27), rheumatoid factor (RF); anti-cyclic citrullinated peptides (anti-CCP); human immunodeficiency virus
(HIV); Hepatitis B and C virus (Hep B/C)), dactylitis severity score (DSS), Leeds Dactylitis Index (LDI), Leeds Enthesitis Index (LEI),
Spondyloarthritis Research Consortium of Canada enthesitis score (SPARCC), Body Surface Area (BSA),  Psoriasis Area Severity Index (PASI),
Target Nail Psoriasis Severity Index (target NAPSI), Dermatology Life Quality Index (DLQI)), tender joint count (TJ), swollen joint count (SJ),
visual analogue scale  (VAS), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index
(BASFI), Assessment of Spondyloarthritis International Society (ASAS), Ankylosing Spondylitis Disease Activity Score (ASDAS), Health
Assessment Questionnaire Disability Index (HAQ-DI), Psoriatic Arthritis Disease Activity Score (PASDAS), Composite Psoriatic Disease Activity
Index (CPDAI), Disease Activity Index for Psoriatic Arthritis (DAPSA), Disease Activity Score 28 (DAS28), Clinical Disease Activity Index (CDAI),
Simplified Disease Activity Index (SDAI), American College Rheumatology response (ACR) 20, 50 and 70, Psoriatic Arthritis Response Criteria
(PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Medical Outcomes Study Short Form 36 (SF-36), Minimal Disease Activity (MDA),
reactive Protein (CRP), erythrocyte sedimentation rate (ESR), and (&).
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according to flow-chat.
• Urea, uric acid, glucose, potassium, sodium, chlo-
ride, calcium, phosphorous, total protein and albu-
min, alkaline phosphatase and total bilirubin (direct
and indirect, if total bilirubin > upper limit of nor-
mal), fas ting total cholesterol, high density lipopro-
teins, low density lipoproteins and triglycerides,
were collected at screening.
Immunogenicity
One blood sample for determination of anti-golimu -
mab antibodies was collected, at the same moment as
for standard clinical laboratorial parameters, at scree -
ning and after 6 months of treatment. 
Magnetic resonance imaging
A dedicated MRI protocol for identification of inflam-
mation and bone damage in the hand and feet with
high-resolution images for dactylitis assessment was
developed.
Images were acquired before and after intravenous
contrast to map and assess the degree of active inflam-
mation with a high temporal resolution protocol. Mor-
phological sequences (T1W) and fluid sensitive se-
quences (STIR) were used to assess structural changes
in bone, tendons and capsular structures and to corre-
late morphology with edema and inflammation.
Unilateral MRI of the hand and wrist or the feet and
ankle (depending on dactylitis location) was per-
formed, at baseline and week 24. If both hand and feet
were involved the most severely affected area was se-
lected.
MRI examination was performed on a 1.5 Tesla who-
le-body scanner in 5 national imaging centres (Funda-
ção Champalimaud; Dr. Campos Costa Imagiologia Clí-
nica in Santa Maria da Feira, Hospital Particular do
Algarve, Santo Tirso and Hospital do Santo Espírito, An-
gra do Heroísmo). For each Imaging Centre the MRI
protocol was centrally validated before trial acquisitions.
Efficacy assessments
The assessment of dactylitis included: 1) The DSS de-
termined by evaluating each dactylitis digit in a scale of
0 to 3 ((0 = no dactylitis; 1 = mild dactylitis, 2 = mo -
derate dactylitis, 3 = severe dactylitis) and the total
score calculated as the sum of scores for all 20 digits
and thus ranging from 0 to 60 (primary efficacy end-
point). Scores > 0 indicate the presence of dactyli-
tis(14); 2) the DSS 20, 50, or 70 responses, defined
as the percentage of patients achieving at least 20%,
50%, or 70% of improvement in the DSS score; 3) the
LDI based on the ratio of circumference between an
affected finger and the contralateral unaffected finger
(measured using the Leeds dactylometer commerciali -
zed by MIE medical research ltd®) and the tenderness
score (0–3) of each finger with dactylitis15; 4) the LDI
20, 50, or 70 responses, defined as at least 20%, 50%,
or 70% of improvement in the LDI score; 5) number
of patients with tender and non-tender dactylitis
and 6) dactylitis remission defined as a dactylitis
severity score equal to zero.
Enthesitis was assessed through the: 1) LEI tender-
ness on examination was recorded as either present (1)
or absent (0) at the lateral epicondyle, the medial
femoral condyle and the Achilles tendon insertion, all
both on left and right sides16; 2) the SPARCC enthesi-
tis score consisted in the evaluation of tenderness at 16
enthesis sites: humerus medial and lateral epicondyle,
supraspinatus insertion into greater tuberosi ty of
humerus, greater trochanter, insertion of plantar fascia
and Aquilles tendon into the calcaneum, quadriceps in-
sertion into superior border of patella and patellar liga-
ment insertion into inferior pole of patella or tibial tu-
bercle17; and 3) the enthesitis remission defined by the
absence of tender enthesis, according to the LEI score.
For joint assessment, the tender joint count of 68
joints and the swollen joint count of 66 joints were
considered, according to the EULAR handbook18.
Patient’ and physician’ global assessments for di -
sease activity (arthritis and psoriasis), for arthritis ac-
tivity, for psoriasis activity and for axial activity (only
patients with axial involvement), were determined 
using VAS from 0 to 100mm.
For those patients with axial involvement, as deter-
mined by the investigator, the BASDAI and ASDAS
were additionally applied.
The BSA score corresponding to the percentage of
body surface affected by psoriasis, considering the pa-
tient’s handprint (palm and fingers) as 1% of the body
surface, and the PASI considering the four body sur-
face areas (head, trunk and upper and lower limbs) and
the degree of plaque erythema, scaling and thickness,
were used to determine psoriasis plaque extension and
severity. The PASI score ranges from 0 (no disease) to
72 (maximal disease) and the response PASI 50, 75 and
90 was determined19. The target NAPSI was used for
nail psoriasis assessment. In the target NAPSI the most
severely affected nail at baseline is divided into 4 qua -
drants and 1 point is awarded for each nail matrix (pit-
ting, leukonychia, crumbling, and red spots in the
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lunula) and 1 point for each nail bed changes (ony-
cholisis, splinter hemorrhages, hyperkeratosis, and oil-
drop dyschromia) per quadrant, ranging from 0 to 8
points per quadrant and a maximum total score of 3220. 
Physical function was evaluated using the HAQ-DI
and the BASFI (only for patients with axial involvement).
To assess the health-related quality of life for psori-
asis we used the DLQI and for global health the SF-36.
We considered different composite indexes of disea -
se activity to capture disease activity in several domains,
including the DAS28, the DAPSA, the SDAI and the
CDAI, the PASDAS and the CPDAI. For those with
axial disease we used the ASDAS.
Response criteria included the ACR 20, 50 and 70,
the PsARC, the ASAS 20 and 40 responses, clinical
important, major improvement DASDAS and 
ASDAS inactive disease criteria, the PsAJAI and the
PASI 50, 75 and 90.
The MDA criteria defined as fulfilling 5 of 7 out-
come measures: tender joint count ≤1; swollen joint
count ≤1; psoriasis activity and severity index ≤1 or
body surface area ≤3; patient pain visual analog scale
(VAS) score of ≤15; patient global disease activity 
VAS score of ≤20; Health Assessment Questionnaire
(HAQ) score ≤0.5; and tender entheseal points ≤1, was 
applied as a measure of remission.
The MRI characteristics of the most severely affec ted
dactylitic finger or toe were assessed by changes from
baseline on the dactylitis MRI score at week 2421.
The MRI characteristics of the selected foot and an-
kle or hand and wrist were determined by changes from
baseline in psoriatic arthritis MRI scoring system for
the hands (PSAMRIS-H) and for feet (PSAMRIS-F) at
week 2422,23.
Specific training was given for investigators and 
trial team concerning efficacy assessment tools. 
sAFety And toLerAbiLity
Subjects enrolled in the study were monitored for both
AEs and serious adverse events (SAEs) immediately af-
ter the subject signed the informed consent. 
Subjects having AEs or SAE were monitored with
relevant clinical assessments and laboratory tests, as
determined by the investigator. Actions taken as a re-
sult of AEs and SAEs, and follow-up results were
recorded in the eCRF, as well as, in the subject’s source
documentation. 
Specific orientations for the management of labora-
torial changes under MTX were developed to guide
clinicians during patients monitoring (Figure 5).
eLectronic cAse rePort Form
A dedicated case record form was developed for GO-
DACT at Reuma.pt. Reuma.pt is a web-based register
used by rheumatologists for patient’s information re -
gister, with restricted access by personal credentials as-
signed to the researchers, approved by Comissão Na-
cional de Proteção de Dados (CNPD). Specific fields
for this trial were developed and could only be accessed
by trial investigators at each centre (Figure 6). Each
subject was identified by a unique subject identification
number. 
etHicAL considerAtions
GO-DACT was conducted in accordance to the ethical
principles of the Declaration of Helsinki, Good Clini-
cal Practice and approved by the National Ethics Com-
mittee (CEIC), National Authority of Medicines and
Health Products (INFARMED) and CNPD. The study
is registered at ClinicalTrials.gov with the number
NCT02065713.
Figure 5. Guidance on how to proceed in case of
myelotoxicity and hepatotoxicity to methotrexate 
methotrexate (MTX), upper limit of normal (ULN); alanine
aminotransferase (ALT); aspartate aminotransferase (AST)
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stAtisticAL And AnALyticAL PLAn
sAmPLe size cALcuLAtion
GO-DACT is a study of controls and experimental sub-
jects randomized in blocks of 4 (2:2). A total sample
size of 90 patients was estimate based on assuming the
absolute change in dactylitis severity score from the GO-
REVEAL trial data considering a difference of 2,52 and
a standard deviation of 4,01, to achieve a 0.05 signi -
ficance between groups and a drop out of 10%24. For
sample size calculation, the ps: power and sample size
calculation software was used. An interim analysis was
planned when 50% of the patients have been included.
bAseLine cHArActeristics
All demographic, medical history, previous and cur-
rent therapies, disease characterization, current medi-
cal history among other variables will be listed by treat-
ment group and subject. For these parameters sum-
mary statistics will be provided by treatment group.
Categorical variables will be summarized by frequen-
cy and percentage. Continuous variables will be sum-
marized by mean, median, standard deviation, and in-
terquartile range.
Differences in baseline characteristics will be as-
sessed using Fisher’s exact test (including a generalized
version for variables with more than two categories)
for categorical variables and the non-parametric
Wilcoxon rank-sum test for continuous variables.
PrimAry eFFicAcy endPoint
For each participant, the change in score will be calcu -
Figure 6. Illustrative screens of GO-DACT’ electronic case report form developed in the Rheumatic Diseases Portuguese Register
(Reuma.pt)
Leeds Enthesitis Index (LEI); Spondyloarthritis Research Consortium of Canada enthesitis score (SPARCC); Psoriasis Area Severity Index
(PASI); Body Surface Area (BSA); Target Nail Psoriasis Severity Index (tNAPSI)
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lated as the final score at 24 weeks minus the baseline
score. We will use the Mann-Whitney test to compare
these changes of the dactylitis severity score between
treatment groups. 
The effect of the intervention will be estimated by the
differences between the two treatment arms in the
changes in scores and significance will be assessed at
a=0.05.
secondAry eFFicAcy endPoints
Descriptive statistics will be used to summarize all se -
condary endpoints such as LDI, LEI, SPARCC, tender
68 and swollen 66 joints, patients and physician  VAS,
BASDAI, ASDAS, BASFI, target NAPSI, HAQ-DI, SF36,
DLQI and composite indexes, among others, by treat-
ment group. The changes in scores will be calculated and
comparisons between treatment groups will be made by
the Mann-Whitney test. Fisher’s exact test will be used
to compare in the two groups the proportion of patients
achieving DSS20,50,70, ACR20,50,70, PASI50,75,90,
ASDAS clinical important and major improvements,
ASAS20,40 and MDI responses, among others.
For MRI findings, a descriptive statistic of each lesion,
for individual joints, dactylitis and enthesis, and aggrega -
ted scores by region will be calculated. The data will be
analyzed individually by joint and lesion and as aggrega -
ted scores such as the PsAMRIS-H and the PsAMRIS-F22,23.
Pairwise comparisons between two time-points for each
individual joints, dactylitis and enthesis and for aggre-
gated scores by region will be calculated.
sAFety
The safety analysis population will include all patients
who receive at least one golimumab/placebo dose and
had at least one post-dose safety assessment. All safety
parameters will be summarized and presented in ta-
bles based on this safety population. Adverse events
will be analyzed, and the incidence summarized by the
total number of patients in each treatment group ex-
periencing a given event. Patients will be assigned to
treatment groups as treated.
triAL medicAtion mAnAgement 
The investigational medical product was managed by
Reuma.pt farmácias, a software developed for the GO-
DACT trial, associated to Reuma.pt (Figure 7). This
platform managed the reception, dispensing and ac-
countability of the trial medication, at the 13 local phar-
macies at research sites, throughout the trial. At each
visit, kits were assigned to each patient according to
his previously randomized study arm and the number
of kits for that visit described by the study protocol in
a double blinded designed. 
Prior to trial activities, specific training for the use of
Reuma.pt farmácias was given to pharmacists and tri-
al coordinators. 
FinAL remArks
GO-DACT is the first randomized controlled trial de-
veloped to study dactylitis as primary endpoint in pso-
Figure 7. Illustrative screens of Reuma.pt Farmácias, a dedicated software developed in Rheumatic Diseases Portuguese Register
(Reuma.pt) for trial medication management, available at http://reuma.pt/farmacias.html
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riatic arthritis patients. Both clinical and imaging out-
comes were used to assess the effect of golimumab or
placebo both in combination with methotrexate, in the
improvement of dactylitis at week 24. The main 
objective of GO-DACT is therefore to provide evidence
to improve the treatment algorithm and care of psori-
atic arthritis patients with active dactylitis.
AcknoWLegments
To participating patients.
To pharmaceutics, nurses and study coordinators of participating
centres.
To rheumatology physicians contributing to trial implementation
or patients’ recruitment:
Catarina Resende, Carlos Miranda Rosa, Rita Barros, Patrícia Nero,
Joana Antunes, Paulo Filipe, Maria Carmo Afonso, Sérgio Alcino, 
Daniela Peixoto, Lúcia Costa, Anabela Barcelos, Filipe Vinagre, 
Fatima Godinho, Augusto Faustino, Ligia Silva, José António Pereira
da Silva, Cátia Duarte, Paulo Monteiro e Maura Couto.
To Blueclinical and NovaCRU 
To Serviço Especializado Epidemiologia e Biologia Molecular –
SEEBMO
To Fundação Champalimaud (Luís Rosa and technical team), Dr.
Campos Costa (Alberto Vieira and technical team), MRI technical
team of Hospital de Santo Espirito da Ilha Terceira and of Insti-
tuto de Ciências Nucleares Aplicadas à Saúde.
To Sociedade Portuguesa de Reumatologia. 
To Reuma.pt Coordination Board and its national coordinator Maria
José Santos.
This investigator-initiated trial was supported by a research grant
from MSD. 
Special acknowledgments to Raquel Dezerto and Carolina Moura.
corresPondence to
Elsa Vieira de Sousa
Unidade de Investigação em Reumatologia 
Instituto de Medicina Molecular 
Edifício Egas Moniz 




1. Mease PJ. Psoriatic arthritis: update on pathophysiology, as-
sessment and management. Ann Rheum Dis. 2011;70 Suppl
1:i77-84.
2. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P,
Mielants H. Classification criteria for psoriatic arthritis: devel-
opment of new criteria from a large international study. Arthri-
tis Rheum. 2006;54(8):2665-2673.
3. Rose S, Toloza S, Bautista-Molano W, Helliwell PS, Group GDS.
Comprehensive treatment of dactylitis in psoriatic arthritis. J
Rheumatol. 2014;41(11):2295-2300.
4. Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis
in psoriatic arthritis: a marker for disease severity? Ann Rheum
Dis. 2005;64(2):188-190.
5. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-
Felquer M, Armstrong AW, et al. Group for Research and As-
sessment of Psoriasis and Psoriatic Arthritis 2015 Treatment
Recommendations for Psoriatic Arthritis. Arthritis Rheumatol.
2016;68(5):1060-1071.
6. Vieira-Sousa E, Machado PM, Costa J, Ribeiro A, Aguiar R,
Cerqueira M, et al. Portuguese Recommendations for the Use of
Biological Therapies in Patients with Psoriatic Arthritis—2015
Update. Acta Reumatol Port. 2015;40(3):275-290.
7. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados
M, et al. European League Against Rheumatism (EULAR) rec-
ommendations for the management of psoriatic arthritis with
pharmacological therapies: 2015 update. Ann Rheum Dis.
2016;75(3):499-510.
8. Wendling D, Lukas C, Prati C, Claudepierre P, Gossec L,
Goupille P, et al. 2018 update of French Society for Rheuma-
tology (SFR) recommendations about the everyday manage-
ment of patients with spondyloarthritis. Joint, bone, spine : re-
vue du rhumatisme. 2018.
9. Orbai AM, Weitz J, Siegel EL, Siebert S, Savage LJ, Aydin SZ, et
al. Systematic review of treatment effectiveness and outcome
measures for enthesitis in psoriatic arthritis. J Rheumatol.
2014;41(11):2290-2294.
10. Kavanaugh A, Mease P. Treatment of psoriatic arthritis with tu-
mor necrosis factor inhibitors: longer-term outcomes including
enthesitis and dactylitis with golimumab treatment in the
Longterm Extension of a Randomized, Placebo-controlled Study
(GO-REVEAL). J Rheumatol Suppl. 2012;89:90-93.
11. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum.
1973;3(1):55-78.
12. Fonseca JE, Lucas H, Canhao H, Duarte R, Santos MJ, Villar M,
et al. Recommendations for the diagnosis and treatment of la-
tent and active tuberculosis in inflammatory joint diseases can-
didates for therapy with tumor necrosis factor alpha inhibitors:
March 2008 update. ACTA REUMATOL PORT. 2008;33(1):77-
-85.
13. Duarte R, Campainha S, Cotter J, Rosa B, Varela P, Correia A, et
al. Position paper on tuberculosis screening in patients with im-
mune mediated inflammatory diseases candidates for biologi-
cal therapy. Acta Reumatol Port. 2012;37(3):253-9.
14. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester
GR, Schneider U, et al. Sustained benefits of infliximab thera-
py for dermatologic and articular manifestations of psoriatic
arthritis: results from the infliximab multinational psoriatic
arthritis controlled trial (IMPACT). Arthritis Rheum.
2005;52(4):1227-1236.
15. Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner
DE. Development of an assessment tool for dactylitis in patients
with psoriatic arthritis. J Rheumatol. 2005;32(9):1745-1750.
16. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoria -
tic arthritis: assessment of existing measures and development
of an instrument specific to psoriatic arthritis. Arthritis Rheum.
2008;59(5):686-691.
17. Maksymowych WP, Mallon C, Morrow S, Shojania K, Olszyns-
ki WP, Wong RL, et al. Development and validation of the
Spondyloarthritis Research Consortium of Canada (SPARCC)
Enthesitis Index. Ann Rheum Dis. 2009;68(6):948-953.
18. P.L.C.M. van Riel DLS. Eular Handbook of Clinical Assessments
in Rheumatoid Arthritis. 4th ed: Alphen aan den Rijn: Van
Zuiden Communications B.V.; 2004.
19. Fredriksson T. Oral treatment of psoriasis and pustulosis palmo-
plantaris with Ro 10-9359. Dermatologica. 1978;157 Suppl
1:13-18.
20. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for
ÓRGÃO OFICIAL DA SOCIEDADE PORTUGUESA DE REUMATOLOGIA
92
the Go-DaCt protoCol
evaluation of nail psoriasis. J Am Acad Dermatol.
2003;49(2):206-212.
21. Healy PJ, Groves C, Chandramohan M, Helliwell PS. MRI
changes in psoriatic dactylitis—extent of pathology, relation-
ship to tenderness and correlation with clinical indices.
Rheumatology (Oxford). 2008;47(1):92-95.
22. Glinatsi D, Bird P, Gandjbakhch F, Mease PJ, Boyesen P, Peterfy
CG, et al. Validation of the OMERACT Psoriatic Arthritis Mag-
netic Resonance Imaging Score (PsAMRIS) for the Hand and
Foot in a Randomized Placebo-controlled Trial. J Rheumatol.
2015;42(12):2473-2479.
23. Ostergaard M, McQueen F, Wiell C, Bird P, Boyesen P, Ejbjerg B,
et al. The OMERACT psoriatic arthritis magnetic resonance
imaging scoring system (PsAMRIS): definitions of key patholo-
gies, suggested MRI sequences, and preliminary scoring system
for PsA Hands. J Rheumatol. 2009;36(8):1816-1824.
24. Kavanaugh A, van der Heijde D, McInnes IB, Mease P, Krueger
GG, Gladman DD, et al. Golimumab in psoriatic arthritis: one-
year clinical efficacy, radiographic, and safety results from a
phase III, randomized, placebo-controlled trial. Arthritis
Rheum. 2012;64(8):2504-2517.
